Monte Rosa Therapeutics (GLUE) logo

Monte Rosa Therapeutics (GLUE) stock

Molecular glue medicines , market cap $761M

$8.64
-3.03%

Why is GLUE down?

Down 5% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%.

  • Its Nov 5 results: research and development expenses were $45.4M, from $36.7M a year before. It fell 5% on Nov 5.

Sources: Price history, Nov 5, 2026; Company release, Nov 5, 2026

−2Long-term trend below a falling 200-day average, down over one year

Tell me next time GLUE moves

Free account, no card. An optional alert when GLUE moves or its score changes.Pro, $1 for a first month. An optional alert when GLUE moves or its score changes.Pro, 7 days free with a card. An optional alert when GLUE moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on GLUE →4 more reasons why GLUE fell on Nov 5, from its filings, with the other side, the timeline, and its peers, for Pro members.
Quality Score
-8
Poor
In its industry
#246of 273
Checks firing
1of 14
Trending down
From 52-week high
-66.5%
under its best in a year

GLUE's Quality Score rose 1 point on Fri, Nov 20, to -8. More shares traded than usual.

Follow GLUE's trial news. Pro members can get an alert when Monte Rosa Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when GLUE files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2026“…(AR) mutations; Phase 2 data update expected in 2027; updated Phase 1/2 study data expected this year”Trial data · SEC filing · Nov 5

Key facts on GLUE

Key facts on GLUE
Holding it backSales down 61% on the year
Latest filing8-K, Nov 5 Reported its quarterly results

GLUE in the news

Fri Nov 6Monte dei Paschi's profit beats forecasts as Intesa prepares to launch offer Reuters and 3 more · 1:58 AM ET GLUE closed +3.1% that day.

What's next

Tue Dec 1: Piper Sandler 38th Annual…Investor conference · date confirmed.

Expected to report Tue Mar 16, before the open

After its last 4 reports it closed -2.4% on average, higher 1 of 4 times.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

GLUE catalysts

Coming up

6 more coming up and 8 past catalysts since 2024, with sizes and sources, for Pro members.

What's next for GLUE, and how long its cash lasts

Next step the company has named

2026“…metastatic castration-resistant prostate cancer (mCRPC) patients with androgen receptor (AR) mutations; Phase 2 data update expected in 2027; updated Phase 1/2 study data expected this year”Trial data · SEC filing · Nov 5

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
Oral MRT-2359 in Selected Cancer PatientsPhase 1/2 · Active · 174 people · main data estimated Dec 2026 · NCT05546268

2 more trials, 6 more milestones and 32 filings, for Pro members.

Cash runway

The company says its cash lasts into 2029 (8-K, Nov 5).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Feb 11, 2026)
  • At-the-market share sales program (S-3ASR, filed Feb 11, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

An officer, Matthew Bowen, sold 13 shares on Oct 5. 30 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Markus Warmuth’s 17 filings and quotes.

Get an alert when GLUE files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How GLUE ranks in Biotech

GLUE is #246 of 273 by Quality Score.

How GLUE ranks in Biotech
RankStockQuality Score
246Monte Rosa Therapeutics (GLUE) logoGLUEMonte Rosa Therapeutics-8

More in Biotech

When does GLUE report earnings, and what happens after?

Expected to report Tue Mar 16, before the open (in 115 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What GLUE reported on Nov 5, 2026

The quarter

The figures are not read from the release yet.

“The increase was primarily driven by recognition of collaboration revenue from the $50.0 million milestone triggered by the initiation of the Novartis Phase 2 study of MRT-6160 (DDY391) in participants with Sjögren's disease.”

The filing on EDGAR

Where the sales came from

GLUE's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The decrease of $43.4 million was primarily due to operational use of cash.”

From its results filing (SEC filing · Nov 5)

1 more sentence, for Pro members.

The numbers

Market value
$761M
today
Sales
$70.3M
down 61.3% on the year
Free cash flow
-$174M
last 12 months

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on GLUE: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-2.8%+0.6%-5.3%
May 7Aug 6Nov 5
ReportedGapReaction5
days
Nov 5, 2026Before open-3.1%-5.3%-4.7%
Aug 6, 2026Before open+0.1%+0.6%+2.2%
May 7, 2026Before open-0.7%-2.8%-7.0%

GLUE closed higher after 1 of its last 4 reports.

All 4 reports, and GLUE's Quality Score going into each

GLUE sales and profit by year

Sales and profit by year

Sales grew every year from 2023 to 2025, to $124M. It lost money in each of the three years.

GLUE has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on GLUE, and all 14 on every stock.Get in free →See the top 3 →Start Pro

GLUE RSI on Nov 20: 27.2, below its 50-day and 200-day averages

Not scored

RSI 27.2, MACD below signal, below both averages. Not scored.

The deep dive on GLUE

8 more findings on GLUE, each with its source, for Pro members.

GLUE share count over time

Shares: 23.5% more than a year ago (to Sep 30).

Shares of GLUE outstanding, as filed
Shares
outstanding
As
of
85.5MOct 30, 2026
85.3MJul 31, 2026
84.5MMay 1, 2026
80MMar 2, 2026
Offerings, shelves, and splits of GLUE, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3ASR)Feb 11, 2026
Priced a sale of sharesJan 9, 2026
Registered shares for a later sale (S-3)Mar 20, 2025
Priced a sale of sharesMay 16, 2024

GLUE insider trades

3 insiders sold $451K across 3 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellMatthew Bowen$137.28Principal Accounting Officerat $10.56 on Oct 5, filed Oct 6

All 3 insider filings on GLUE from the last six months, for Pro members.

All GLUE insider trades

GLUE's officers and directors

Officers and directors with a Form 4 in the last 12 months.

One more officer or director files at GLUE.

See insider trades by person

Which ETFs hold GLUE?

In ETFs: GLUE is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

173 employeesBoston, MAmonterosatx.com

What Monte Rosa Therapeutics says it competes with

“The biotechnology industry is extremely competitive in the race to develop new products and the industry is characterized by a high level of innovation and strong emphasis on proprietary products and intellectual property rights.”

From its annual report, SEC filing · Mar 17, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on GLUE and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn GLUE's score around: 9 things
  • 7 more filings explained, a plain line each
  • 6 more things pulling GLUE's score down
BreakawayOct 6Matthew Bowen sold GLUE$137 at $10.56, filed Oct 6

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: GLUE's Quality Score is -8 (Poor), #246 of 273 in Biotech. Insiders sold $451K in the last 6 months (Form 4).

What does GLUE's Quality Score say?

GLUE scores -8 today, which Breakaway calls Poor. It is #246 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 5% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%. Shares: 23.5% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is GLUE's Quality Score?

GLUE scores -8 today, which Breakaway calls Poor (below zero). That is #246 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GLUE's -8.

Are insiders buying GLUE?

3 insiders sold $451K across 3 filings in the last 6 months. No open-⁠market buys on record. The newest is Matthew Bowen, Principal Accounting Officer, who sold $137.28 on Oct 5. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Monte Rosa Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.